Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit

Abstract

The McMaster Immune Thrombocytopenia (ITP) Summit, held on October 27, 2023, was an educational seminar from leading experts in immune thrombocytopenia and related disorders geared toward hematologists, internists, immunologists, and clinical and translational scientists. The focus of the Summit was to review the mechanisms, diagnosis, and treatment of primary versus secondary ITP. Specific objectives were to describe the unique features of secondary ITP, and to review its mechanisms in the context of autoimmune disease and infection. The key messages in this Summit were: (1) ITP is a heterogeneous disease, and genetic and immunologic insights may help classify patient subtypes; (2) exploring the autoimmune mechanisms and their association with hypogammaglobulinemia in patients with secondary ITP could improve our understanding of ITP and its subtypes; (3) investigating the mechanisms of ITP in the context of infections caused by viruses such as CMV, HIV, dengue, and hepatitis C, or bacteria such as H. pylori, or vaccinations could provide insight into the causes of ITP. A better understanding of secondary ITP could help elucidate the pathogenesis of ITP.

 

MissingLinkText

Keywords

bleeding - immune thrombocytopenia - platelet - immunology - infection

Introduction

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a platelet count below 100 × 10⁹/L (normal range 150–400 × 10⁹/L), which leads to an increased risk of bleeding, and the lack of an alternate, non-immune-mediated cause of the thrombocytopenia such as hypersplenism and aplasia among others. Primary ITP is an isolated thrombocytopenia with no other apparent immune disease or abnormality, while secondary ITP is immune-mediated thrombocytopenia that is associated with other diseases or conditions including autoimmune or immunological disorders, infection, and malignancy. The focus of the 2023 McMaster ITP Summit, held on October 27, 2023, was to examine the causes and mechanisms of secondary ITP. The curriculum was divided into (1) an overview of ITP, (2) ITP and autoimmunity, and (3) ITP and infection.

 

MissingLinkText

Overview of ITP

ITP is caused by platelet autoantibodies, cytotoxic T cells, and other factors that accelerate platelet destruction and/or inhibit platelet production.[1] Both primary and secondary ITP may have overlapping mechanisms of thrombocytopenia and exhibit similar signs and symptoms. The mechanism of ITP associated with certain infections (e.g., varicella, HIV, and hepatitis C) is at least partly related to molecular mimicry, whereby antibodies occurring in response to the infection subsequently recognize platelet antigens.[2] [3] Treating the underlying cause is an important principle of treatment for secondary ITP; however, this is often challenging and not always effective for improving the thrombocytopenia.

Secondary ITP

Approximately 10 to 20% of ITP is secondary to an underlying disorder[4] [5] [6] [7] including: (a) autoimmune diseases (e.g., SLE or anti-phospholipid syndrome [APS]); (b) post-infectious or post-vaccine (e.g., HIV, H. pylori, cytomegalovirus [CMV], dengue, measles-mumps-rubella [MMR] vaccine); (c) alternated immune states (common variable immunodeficiency [CVID], autoimmune lymphoproliferative syndrome [ALPS]); or (d) malignancy (lymphoma, CLL). It is important to identify such secondary forms because the clinical manifestations, pathophysiology, natural history, treatments, and treatment responses for secondary ITP typically differ from primary ITP.

The diagnosis of secondary ITP is clearest when remission follows an intervention to treat the underlying disorder such as eradication of infection (e.g., H. pylori). In other situations, the relationship is assumed based on co-existence of other disorders such as SLE and APS. Patterns of secondary ITP have changed over time; for example, HIV-associated ITP has declined with the introduction of highly aggressive anti-retroviral therapy (ART). New genetic markers may help identify some patients with ITP associated with CVID, ALPS, and other immunological conditions.[8] [9] Genetic polymorphisms related to T cell function, cytokine levels, and IgG-Fc receptor function have been identified in some patients with primary ITP.[10] Insights from genetic analyses combined with biochemical and fundamental immunologic investigation may help differentiate between patients with (1) a “normal” immune system who develop ITP due to cross-reactivity with an external stimulus (e.g., post-viral childhood ITP, MMR vaccine); (2) a controlled autoimmune tendency that can be perturbed or rectified (checkpoint inhibitors, alemtuzimab); and (3) a fundamental alteration in immune responses (e.g., Evans, ALPS). These advances may help further classify patients with secondary ITP.

 

MissingLinkText

Diagnosis of Primary Versus Secondary ITP

ITP remains a diagnosis of exclusion. The evaluation of adults with possible ITP includes a history and physical examination, review of the peripheral blood smear, and necessary investigations to rule out non-immune causes of thrombocytopenia or secondary causes of ITP. Patients with ITP typically have isolated thrombocytopenia with normal white and red blood cell morphology. Platelets are normal to large in size with normal granularity. Further testing to confirm the diagnosis (e.g., glycoprotein-specific antibodies, bone marrow evaluation, thrombopoietin levels) has not been endorsed by evidence-based guidelines for all ITP patients.[11] [12] Once the diagnosis of ITP is considered, the next step is to assess if it is primary or secondary. Current recommendations are that all adult patients should be screened for hepatitis C and HIV. H. pylori testing is valuable in high prevalence regions, and ANA antibodies can corroborate an immune cause. Laboratory testing may also inform treatment decisions. For example, in the pediatric OBS'CEREVANCE cohort, ANA-positive children (n = 64) had a 54% response rate with hydroxychloroquine.[13] Similarly, patients who are ANA-positive or APLA-positive may have a higher risk of thrombosis after thrombopoietin receptor agonist medications (TPO-RAs)[14] [15] and hepatitis B screening should be done for all patients before receiving rituximab.

 

MissingLinkText

Novel Targets for ITP Treatment: Informing Disease Mechanism

The last two decades have produced multiple regulatory agency-approved therapeutics for the management of ITP. Multiple new agents are now in late-stage clinical development, many of which target new mechanistic pathways, which can help elucidate underlying pathobiology.[16]

Efgartigimod is a parenterally administered human IgG1 antibody Fc-fragment engineered for increased affinity to the neonatal Fc receptor (FcRn), a receptor critical to the physiologic half-life of IgG.[17] [18] Efgartigimod competes with IgG for the FcRn, increasing degradation of IgG and reducing the half-life of circulating IgG from 21 days to (depending upon dose) approximately 7 days.[19] By dropping IgG levels by approximately 60%, the level of pathologic platelet autoantibodies theoretically could drop significantly, thereby reducing platelet opsonization and destruction in the reticuloendothelial system. The safety and efficacy of intravenous efgartigimod in ITP has been demonstrated in successful phase 2 and phase 3 studies.[20] [21] However, a phase 3 study evaluating the safety and efficacy of subcutaneously administered efgartigimod failed to show a significant difference in efficacy in comparison to placebo.[22] The efficacy of the anti-FcRn molecule strengthens the support for an autoantibody mechanism of ITP.

Rilzabrutinib is a highly selective, small-molecule inhibitor of the Bruton tyrosine kinase (BTK). Inhibition of BTK targets potential pathophysiologic mechanisms in ITP, including B cell maturation and differentiation into plasma cells, antibody production by B cells, and activation of mononuclear phagocytes that destroy platelets.[23] Rilzabrutinib results in fewer off-target effects than ibrutinib, and does not cause platelet dysfunction.[24] Rilzabrutinib demonstrated promising safety and efficacy in a phase 1b/2 study of patients with ITP largely refractory to other treatment options, with a 40% response rate at the top dose.[25] A phase 3 clinical trial showed a higher proportion of adult patients receiving rilzabrutinib achieving a durable platelet response in comparison to placebo.[26] [27] The efficacy of rilzabrutinib provides evidence for a B cell mechanism for ITP.

Several other therapeutics, both novel and repurposed, are currently in phase 2 or phase 3 studies in patients with ITP. Ianalumab, a humanized monoclonal antibody that blocks the B cell activating factor receptor (BAFF-R) and thereby inhibits activation of B cells,[28] is currently being evaluated in two randomized, placebo-controlled phase 3 study of patients with ITP. A separate phase 2 study is evaluating ianalumab monotherapy in patients with relapsed, refractory ITP. Iptacopan is an oral complement factor B inhibitor[29] currently being evaluated in a clinical trial that includes patients with ITP and cold agglutinin disease. Sovleplenib is a new spleen tyrosine kinase (Syk) inhibitor currently being developed for ITP in China.[30] Daratumumab and mezagitamab are anti-CD38 monoclonal antibodies currently in development for ITP.[31] [32] A combined anti-BAFF and anti-APRIL monoclonal antibody is being evaluated in ITP, hemolytic anemia, and cold agglutinin disease.[33] As these pathways become clarified, the underlying causes of ITP will be further elucidated, which will help explain the heterogeneity among patients with primary ITP.

 

MissingLinkText

 

MissingLinkText

ITP and Autoimmunity

There is considerable overlap between secondary ITP and other autoimmune diseases, such as SLE and CVID. In a study of 886 children with chronic ITP, 21% developed antinuclear ANAs, but clinical SLE was much less frequent.[13] In a report from the McMaster ITP Registry, 3.6% of ITP patients had SLE, 1.1% had CVID, 3.9% had Evans syndrome, 1.7% had APS, and 4.1% had other autoimmune conditions.[7]

ITP in the Context of Autoimmune Disease

Understanding the mechanisms of autoimmune diseases can provide insights into ITP pathogenesis. For example, possible mechanisms of SLE include: abnormal clearance of apoptotic cell material; dendritic cell uptake of autoantigens and activation of B cells; B cell Ig class switching and affinity mutation; development of IgG autoantibodies; immune complexes; and complement activation and cytokine generation.[34]

B cells have been traditionally viewed as key mediators in SLE. In the placebo-controlled BEAT Lupus Trial, the combination of rituximab plus belimumab was associated with lower serum IgG anti-dsDNA antibody levels, suppressed B cell repopulation, and a lower risk for severe flare, with no increased incidence of serious adverse events compared with rituximab alone.[35] In addition, interferons (INF), a group of signaling proteins initially discovered as part of the viral response, have been implicated in SLE pathogenesis. Patients receiving INF therapy for carcinoid tumors have been shown to develop lupus-like illnesses.[36] Plasmacytoid dendritic cells have elevated INF signature in those with SLE compared with healthy controls.[37] Anifrolumab, a fully humanized monoclonal antibody that binds subunit 1 of Type I INF receptor, has been approved for the treatment of SLE patients who are receiving standard therapy.[38] Whether these findings have implications for the management of ITP-associated SLE is uncertain.

 

MissingLinkText

ITP and SLE

SLE is a systemic disease in which thrombocytopenia is present in approximately 16% of patients.[39] SLE is diagnosed with the presence of ANAs at a titer ≥ 1/80, plus clinical findings, including thrombocytopenia, and immunological findings including low serum complement and anti-dsDNA or anti-Sm autoantibodies.[40] ITP occurring in the context of SLE can be considered secondary or SLE-associated ITP. Here we discuss the risk of SLE development in patients with ITP, the implications of positive ANA, and how the association of ITP with SLE impacts the choice of ITP treatment.

The cumulative incidence of SLE in patients with ITP is approximately 5% at 5 years, with the highest risk in young women.[41] [42] In a recent prospective study of 886 children with chronic ITP, 38 (4.3%) developed SLE after a median of 2.8 years from ITP diagnosis (87% were female and the median age was 15 years). In total, 20.5% of children with ANA ≥1/160 at diagnosis of primary ITP developed SLE during follow-up.[13] Conversely, the prevalence of ANA seropositivity among patients with ITP is as high as 40% (with a titer ≥ 1/160), but the clinical significance is uncertain.[43]

The presence of a positive ANA has been associated with a higher probability of chronic ITP in both children and adults.[6] [44] It has not been associated with ITP disease severity or response to first-line ITP therapy.[43] However, ANA-positivity has been associated with higher response to rituximab but a shorter duration of response[45] and an increased risk of thrombosis.[15]

In patients with SLE, the concomitant thrombocytopenia may be caused by several factors including ITP, drugs (immunosuppressants), infection, etc. Most patients with SLE-associated ITP have mild thrombocytopenia (platelets >50 × 10⁹/L) and treatment is often not needed (approximately 5% of patients with SLE require ITP treatments). First-line treatment is typically corticosteroids with or without IVIG, similar to primary ITP.[46] [47] [48] Hydroxychloroquine, which is the cornerstone treatment for chronic SLE,[49] may improve thrombocytopenia in some patients with SLE-associated ITP.[50] [51] The preferred second-line treatment is rituximab, with response rates higher than in primary ITP (approximately 80%).[52] [53] Other immunosuppressants such as mycophenolate or calcineurin inhibitors may be useful, while splenectomy is often avoided in SLE patients due to a higher baseline risk of infection and thrombosis.[46] [49] [54] TPO-RAs should be used with caution in patients with antiphospholipid antibodies due to an increased risk of thrombosis.[14] [48] [55] [56] [57] Some B cell targeted therapies may be useful in the future in the setting of ITP-associated SLE (e.g., daratumumab, belimumab, or ianalumab).[16] [58]

 

MissingLinkText

ITP and Primary Antibody Defects

Primary immune defects of immunoglobulins are due to B cell depletion or under-development, loss of production of one or more immunoglobulin (Ig) isotypes, or loss of functional antibody production. As a group, genetic antibody defects are the most prevalent immune defects in clinical practice and are found in all ages. Of all the B cell defects that are associated with thrombocytopenia, the most common is CVID, which has an estimated incidence of 1:25,000 to 1:50,000. The majority of patients with CVID are diagnosed between the ages of 20 and 45.[59] [60] This immune defect is defined by a low serum IgG, deficiency of serum IgA and/or IgM, and failure to mount an antibody response, typically after vaccination. Approximately 25% of patients with CVID will develop autoimmune conditions, with ITP being the most common.[59]

It is unclear why autoimmunity occurs in states of B cell deficiency. This may relate to immaturity of the B cell population, lack of somatic hypermutation, loss of isotype switched memory B cells, and an excess of serum BAFF.[61] [62] [63] [64] Additional defects include decreased numbers of CD4+ T cells, and T cell activation defects, and fewer regulatory T cells (Tregs).[65] [66] Genetic defects can be identified in approximately 30% of CVID patients.[67] [68] Many different genetic defects have been reported relating to stem cell commitment in the bone marrow, germinal center migration and activation, and the final steps of memory B cell commitment. In a study of 405 CVID patients, ITP was diagnosed in 67 (16.5%), including 25 (37.3%) in whom a gene defect was identified.[69]

The initial treatment of ITP in patients with antibody defects involves corticosteroids and high-dose IVIG. In a study of 326 patients with CVID, 35 developed a hematologic autoimmune disease, and of those, 30 were diagnosed before the institution of periodic IVIG replacement.[70] This suggests that routine periodic immunoglobulin replacement therapy may reduce the risk of autoimmune disease in this immune defect. Rituximab has been widely used in the setting of CVID-associated ITP and often provides long-term benefit.[71] Other options include TPO-RAs[72] or potentially splenectomy, which is sometimes performed for an increasingly large spleen and concern for lymphoma. Previous splenectomy did not increase mortality in CVID patients receiving immunoglobulin replacement therapy in several large cohort studies.[59] [73]

 

MissingLinkText

 

MissingLinkText

ITP and Infection

As early as the 1940s, viruses such as varicella and rubella were frequently reported to be associated with pediatric acute ITP.[74] [75] Certain infections have been recognized as having a pathophysiologic role in the development of ITP including CMV, H. pylori, dengue, HIV, and hepatitis C.[4] [76]

ITP Secondary to CMV, H. Pylori, and Dengue

Cytomegalovirus (CMV)-associated ITP: CMV has been implicated as a possible causative agent of thrombocytopenia including ITP in children and adults or as a possible trigger for worsening ITP. CMV can infect megakaryocytes and platelets and be transported into cells by anti-CMV antibodies. CMV disease can cause pancreatitis, colitis, pneumonitis, fever, transaminitis, atypical lymphocytes on smear, or refractory ITP. CMV-associated ITP tends to affect very young children, often less than 1 year old and in immunosuppressed patients. For patients with CMV-associated ITP, IVIG is recommended, while corticosteroids or immunosuppressive medications should be avoided. Anti-CMV medications have been effective, primarily ganciclovir, which is often used in combination with IVIG; however, ganciclovir can cause bone marrow suppression, especially thrombocytopenia, after 2 weeks of treatment.

Helicobacter pylori-associated ITP: In 1998, Gasbarrini et al[77] found that eradication of H. pylori increased platelet count in a small number of thrombocytopenic patients. The most accepted mechanism is cross-reactive antibodies or molecular mimicry of the CagA protein with platelet glycoproteins including GPIIb/IIIa, Ib/IX, and Ia/IIa. In Japan, testing for H. pylori in patients with new-onset ITP is routine because H. pylori eradication often results in ITP resolution. High rates of response have also been seen in the Middle East and Italy.[78] In North America, even if active H. pylori infection is detected, eradication does not often lead to improvement in platelet count[79] likely because of population differences in HLA class II or different strains of H. pylori.

Dengue fever: Dengue virus (DENV) can cause severe ITP. Bleeding is often due to associated disseminated intravascular coagulation, disrupted platelet function, and capillary leak. DENV enters the bloodstream from the mosquito, binds to platelets via heparin sulfate proteoglycans and DC-SIGN, enters platelets, and the viral particle is uncoated, releasing ssRNA into the cytosol leading to viral replication. Platelet activation may accelerate DENV entry into platelets, and higher degree of interaction between dengue and platelets may increase platelet activation.[80] Acquiring an additional strain of DENV after infection or vaccination against a different strain can worsen the disease due to antibody-mediated enhancement with efficient delivery of the virus to monocytes and platelets, leading to rapid replication and inflammation. Thus, there is no worldwide vaccination against dengue. In patients with DENV hemorrhagic fever, increased platelet count has been observed after treatment with IVIG.[81]

 

MissingLinkText

ITP Secondary to HIV and HCV

HIV-associated ITP: An association between the acquired immunodeficiency syndrome (AIDS) and chronic ITP was described before the HIV virus had been isolated and characterized.[82] Several mechanisms have been reported by which HIV infection could produce thrombocytopenia; however, the ability of effective ART to improve platelet count demonstrated the relationship between viral replication, expression of viral-related proteins, and the response of the host to platelets. Prior to the advent of ART, thrombocytopenia was reported in 5 to 30% of patients with AIDS and HIV infection depending upon disease stage.[83] [84] [85] [86] The thrombocytopenia was frequently mild and more prevalent in patients with advanced HIV infection defined as a CD4-lymphocyte count of <200/µL, clinical AIDS, intravenous drug users, or concomitant infections with CMV and/or hepatitis C virus (HCV).[87] Several causes of thrombocytopenia in this setting should be considered including thrombotic thrombocytopenic purpura (TTP), bone marrow infection, and medication-associated bone marrow suppression. ITP is more likely in patients with no other cytopenias and higher CD4 counts.

Effective ART changed the course and the management of HIV-associated ITP.[88] [89] [90] HIV-associated ITP is responsive to prednisone, IVIG, anti-RhD, and splenectomy[91] [92] [93] but ART resulted in a longer response and sustained remissions in HIV viral load negative patients without any of these ITP-directed treatments. In a cohort study of 31 patients with HIV-associated ITP, 25 of 30 evaluable patients (83%) achieved a platelet count response after ART therapy, including 7 who achieved complete platelet count response. After a median follow-up of 48 months, 22 patients relapsed. Responses to corticosteroids, IVIG, anti-RhD, and splenectomy were variable. Four patients died due to variceal bleeding, refractory Evans syndrome, hepatic failure, and advanced HIV.[94] TPO-RAs[95] and effective treatment of hepatitis C[96] [97] [98] are important treatment considerations for patients with HIV-associated ITP.

Hepatitis C virus (HCV)-associated ITP: The HCV was first identified in 1989 with an antibody screening test the same year.[99] The NHANES III study estimated that 3.2 million persons in the US are HCV positive.[100] HCV infection has been associated with liver cirrhosis, immunopathologic and autoimmune manifestations including hypergammaglobulinemia with polyclonal and monoclonal gammopathy, cryoglobulinemia, lymphoma, rheumatoid arthritis, Lichen planus, and ITP.[97] [101] [102] [103] The clinical presentation of HCV-associated ITP can be confusing in the presence of cirrhosis, portal hypertension, and splenomegaly. Six cross-sectional studies have reported serological evidence of HCV infection in 159/799 chronic ITP patients (20%).[104] In a US study, 76 HCV-positive ITP patients without cirrhosis were compared with 149 HCV-negative ITP patients. Severe thrombocytopenia was less frequent among the HCV patients (3 [4%] versus 69 [46%], P = 0.001); however, 56 (74%) HCV patients had platelet counts of <50 × 10⁹/L.[105]

Treatment of HCV-associated ITP should focus upon suppression of the virus[103] and there is often a need to increase the platelet count before starting antiviral treatment. Prednisone, IVIG, anti-RhD, and TPO-RAs are reasonable treatments for HCV-associated ITP.[104] [106] [107] Eltrombopag is approved to support patients receiving HCV treatment[106] and avatrombopag and lusutrombopag for thrombocytopenia in patients with liver disease.[107] Eradication of HCV can result in a sustained platelet count response.[108] However, early and late relapses can occur, and other ITP treatments may be required.[108] [109] [110] Patients with relapsed ITP should be rescreened for HCV reactivation.

 

MissingLinkText

Vaccine-related ITP

The association between measles vaccination and ITP was demonstrated by Oski and Naiman in 1966.[111] They showed that platelets dropped in the majority of people vaccinated with the live vaccine, with the lowest counts in the first week and near-complete resolution of the thrombocytopenia by 3 weeks post-vaccination. The attenuated MMR vaccine has since become a routine vaccination of childhood and generally involves an initial dose at 1 year of age, followed by a booster before the age of 6 years.

A large Finnish study showed 23/700,000 children developed ITP post-MMR after a median of 19 days with a median platelet nadir of 4,000/mm³.[112] The thrombocytopenia resolved in more than half of the patients within 1 month, and all but one resolved by 6 months post-vaccine. This study resulted in the US Institute of Medicine Vaccine Safety Committee concluding in 1993 that there is a causal relation between MMR and thrombocytopenia.[113] A more recent systematic review included 12 studies and showed that the incidence of ITP was 0.08 to 4 per 100,000 doses of MMR, suggesting that the risk of ITP after natural infection with measles (6–1,200 per 100,000) is higher than the risk post-vaccination.[114] The 2011 ASH guidelines suggest that children with ITP who are unimmunized should receive their first MMR vaccine. For children who have already received a first dose, titers can be checked to determine if a booster is needed, even if the initial ITP was temporally related to the diagnosis.[115]

Other vaccines have been associated with the development of ITP, including DPT, BCG, pneumococcus, H. influenza, varicella-zoster virus, rubella, hepatitis A and B, influenza, and COVID-19. Emerging global data suggests that the risks of primary infections with many of these viruses generally outweigh the small risk of ITP due to vaccination.[116]

 

MissingLinkText

 

MissingLinkText

Conclusion

The 2023 McMaster ITP Summit provided a summary of key concepts relating to secondary ITP, which can occur in the setting of autoimmune disease, immune dysregulation, infection, or vaccination. Several key takeaway messages were identified to advance our understanding and approach to diagnosis and treatment ([Table 1]).

Table 1 Key messages regarding primary versus secondary ITP

1. ITP is a heterogeneous disorder. Insights from genetic analyses combined with biochemical and fundamental immunologic investigation may help classify ITP subtypes. 2. ITP is a diagnosis of exclusion. At a minimum, investigations in adults should include a thorough history and physical examination, CBC, review of the peripheral blood smear, and testing for hepatis C and HIV. Additional testing should be individualized. 3. Novel agents targeting specific pathways provide insight into the pathophysiology of ITP. 4. Understanding autoimmune disease mechanisms can elucidate the pathobiology of ITP. 5. CVID is commonly associated with ITP. Advancing genetic-based and therapeutic strategies may improve the management of primary immune defects and associated autoimmune manifestations. 6. CMV can cause ITP to become more severe, and, if present, immunosuppressive medication should generally be avoided. 7. The frequency and prognosis of H. pylori-associated ITP varies across geographic regions, with high prevalence and ITP responses noted upon eradication in Japan, Italy, and the Middle East. 8. Among HIV-associated ITP patients, effective ART has resulted in platelet count responses and remissions, almost eliminating ITP as a problem in HIV. 9. Major bleeding occurs more frequently in HCV-positive ITP patients compared with HCV-negative patients despite higher platelet counts. 10. The benefits of vaccinations generally outweigh the small risk of ITP.

Abbreviations: ART, anti-retroviral therapy; CBC, complete blood count; CMV, cytomegalovirus; CVID, common variable immunodeficiency; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ITP, immune thrombocytopenia.

 

MissingLinkText

 

MissingLinkText

Conflict of Interest

D.C. reports consulting fees from Novartis and Sanofi. D.C. also serves on a Data Safety Monitoring Board or Advisory Board for Novartis and Sanofi. C.N. has received author royalties from UpToDate. Consulting fees were received from ArgenX, Novartis, Sobi, Sanofi, and Genzyme, while an ongoing consultancy exists with Janssen. Honoraria were received from Sanofi. Payments for expert testimony were received from the U.S. Department of Defense Vaccine Program and Stein Mitchell Beato & Missner LLP. Travel support was received from Sanofi for ISTH 2024. Unpaid roles include being a medical advisor for ITP Australia and The UK ITP Support Association, and a committee member with ASH Committee on Quality, ISTH Meeting Planning Committee 2025, and a chair on the ASPHO review course. H.A. received grants or contracts from Agios, Amgen, Novartis, Vaderis, and Sobi to their institution. Consulting payments were received from Amgen, Novartis, Alnylam, Agios, Argenx, Alpine, Sobi, and Pharmacosmos. N.C. disclosed participation on a data safety monitoring board or advisory board, and payment for honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or educational events from Amgen, Novartis, Griffols, and Sobi. G.M. disclosed support from McMaster University related to the present manuscript. G.M. has received grants or contracts from Amgen, Argenx, Grifols, Novartis, and Sanofi, and consulting fees from Argenx, Grifols, Novartis, Sanofi, Alpine, and Amgen, along with payments from Amgen, Grifols, and Novartis. Support for attending meetings was provided by Amgen, Grifols, and Novartis. C.C.R. disclosed a consultancy role with Pharming, award committee role with Grifols, and data safety monitoring board role with Otsuka since the initial planning of this manuscript. C.C.R. has received grants or contracts from X4 and NIH USIDNET, and serves on a steering committee for NIH USIDNET. Consulting fees were received from Pharming and X4. C.C.R. also attended meetings and events sponsored by the CIS Summer School 2024, CIS National Meeting 2024, and the California Allergy Immunology Society 2024. Patents are planned, issued, or pending for the use of BTK in inflammatory diseases in CVID. C.C.R. holds a leadership role in the Royal PID group in New York City. H.A.L. has received grants or contracts from Sanofi, and consulting fees from Sanofi, Novartis, and Alpine Immune Sciences. J.B.B. has received consulting fees from Amgen, Novartis, SOBI, UCB, Argenx, Janssen, and RallyBio. D.M.A. declares receiving grants or contract support from the Canadian Institutes of Health Research, Rigel, and Alpine Immune Sciences (all related to ITP), royalties or licenses from UpToDate, and consulting fees from Novartis, Rigel, Amgen, Medison, Sobi, and Argenx (all related to ITP). D.M.A. also serves as an unpaid medical advisor for the Platelet Disorders Support Association. D.M., S.R.C., S.M., H.M., V.R.B., and I.N. declare that they have no conflicts of interest.

Authors' Contribution

All authors contributed to writing the article, providing critical feedback, and helping shape the research described in the article. The section Secondary ITP was written by D.C., the section Diagnosis of Primary versus Secondary ITP was written by C.N., the section Novel Targets for ITP Treatment: Informing Disease Mechanism was written by H.A., the section ITP in the Context of Autoimmune Disease was written by N.C., the section ITP and SLE was written by G.M., the section ITP and Primary Antibody Defects was written by C.C., the section ITP and Infection was written by J.B., the section ITP Secondary to HIV and HCV was written by H.L., and the section Vaccine-related ITP was written by V.B. D.M. took the lead in editing the article, with support from S.R.C., S.M., and H.M. D.A. supervised the project.

• References

• 1 Li Q, Marcoux G, Hu Y. et al. Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP). Autoimmun Rev 2024; 23 (12) 103677
• 2 Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 2009; 113 (17) 4086-4093
• 3 Wright JF, Blanchette VS, Wang H. et al. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol 1996; 95 (01) 145-152
• 4 Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113 (26) 6511-6521
• 5 Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014; 124 (22) 3308-3315
• 6 Moulis G, Germain J, Comont T. et al; CARMEN Investigators Group. Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol 2017; 92 (06) 493-500
• 7 Arnold DM, Nazy I, Clare R. et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv 2017; 1 (25) 2414-2420
• 8 Cines DB. Pathogenesis of refractory ITP: overview. Br J Haematol 2023; 203 (01) 10-16
• 9 Gollomp K, Teachey DT. TORing the impact of sirolimus on immune health. Blood 2023; 141 (03) 212-214
• 10 Georgi JA, Middeke JM, Bornhäuser M, Matzdorff A, Trautmann-Grill K. Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP. Blood Adv 2023; 7 (14) 3710-3724
• 11 Neunert C, Terrell DR, Arnold DM. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3 (23) 3829-3866
• 12 Provan D, Arnold DM, Bussel JB. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019; 3 (22) 3780-3817
• 13 Pincez T, Fernandes H, Pasquet M. et al. Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia. Am J Hematol 2023; 98 (06) 857-868
• 14 Guitton Z, Terriou L, Lega JC. et al. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology (Oxford) 2018; 57 (08) 1432-1438
• 15 Hollenhorst MA, Al-Samkari H, Kuter DJ. Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. Blood Adv 2019; 3 (22) 3515-3521
• 16 Al-Samkari H, Neufeld EJ. Novel therapeutics and future directions for refractory immune thrombocytopenia. Br J Haematol 2023; 203 (01) 65-78
• 17 Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A 2004; 101 (30) 11076-11081
• 18 Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7 (09) 715-725
• 19 Ulrichts P, Guglietta A, Dreier T. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 2018; 128 (10) 4372-4386
• 20 Newland AC, Sánchez-González B, Rejtő L. et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 2020; 95 (02) 178-187
• 21 Broome CM, McDonald V, Miyakawa Y. et al; ADVANCE Investigator Study Group. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2023; 402 (10413): 1648-1659
• 22 Argenx. Argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in adults with primary immune thrombocytopenia (ITP); 2023
• 23 López-Herrera G, Vargas-Hernández A, González-Serrano ME. et al. Bruton's tyrosine kinase—an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol 2014; 95 (02) 243-250
• 24 Langrish CL, Bradshaw JM, Francesco MR. et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J Immunol 2021; 206 (07) 1454-1468
• 25 Kuter DJ, Efraim M, Mayer J. et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med 2022; 386 (15) 1421-1431
• 26 Sanofi. Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia. 2024; available at: https://www.sanofi.com/en/media-room/press-releases/2024/2024-04-23-05-00-00-2867327
• 27 Kuter DJ, Bussel JB, Ghanima W. et al. Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study. Ther Adv Hematol 2023; 14: 20 406207231205431
• 28 Dörner T, Posch MG, Li Y. et al. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis 2019; 78 (05) 641-647
• 29 Risitano AM, Röth A, Soret J. et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol 2021; 8 (05) e344-e354
• 30 Liu X, Zhou H, Hu Y. et al. Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study. Lancet Haematol 2023; 10 (06) e406-e418
• 31 Tsykunova G, Holme PA, Tran HTT. et al. Daratumumab as a treatment for adult immune thrombocytopenia: a phase II study with safety run-in (the DART Study). Blood 2021; 138 (Suppl. 01) 2088
• 32 Fedyk ER, Zhao L, Koch A. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol 2020; 86 (07) 1314-1325
• 33 Broome CM, Arnold D, Piatek C. et al. PB2554: design of a phase 1B open-label study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of povetacicept (ALPN-303) in subjects with autoimmune cytopenias (RUBY-4). HemaSphere 2023; 7 (S3): e691820b
• 34 Ameer MA, Chaudhry H, Mushtaq J. et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus 2022; 14 (10) e30330
• 35 Shipa M, Santos LR, Nguyen DX. et al. Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial. Lancet Rheumatol 2022; 5 (01) e24-e35
• 36 Rönnblom LE, Alm GV, Öberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115 (03) 178-183
• 37 Psarras A, Alase A, Antanaviciute A. et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun 2020; 11 (01) 6149
• 38 Loncharich MF, Robertson I. Anifrolumab in systemic lupus erythematosus. Drugs Today (Barc) 2023; 59 (02) 53-61
• 39 Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80 (01) 14-25
• 40 Aringer M, Costenbader K, Daikh D. et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78 (09) 1151-1159
• 41 Zhu FX, Huang JY, Ye Z, Wen QQ, Wei JC. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Ann Rheum Dis 2020; 79 (06) 793-799
• 42 Maquet J, Lafaurie M, Sailler L, Lapeyre-Mestre M, Moulis G. Correspondence on “Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study”. Ann Rheum Dis 2023; 82 (04) e95
• 43 Moulis G, Aladjidi N, Godeau B. Clinical significance of antinuclear antibodies in primary immune thrombocytopenia. Br J Haematol 2023; 203 (01) 131-135
• 44 Heitink-Pollé KMJ, Nijsten J, Boonacker CWB, de Haas M, Bruin MCA. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood 2014; 124 (22) 3295-3307
• 45 Wang YM, Yu YF, Liu Y, Liu S, Hou M, Liu XG. The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. Hematology 2020; 25 (01) 139-144
• 46 Arnal C, Piette JC, Léone J. et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002; 29 (01) 75-83
• 47 Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005; 64 (09) 1366-1369
• 48 Roussotte M, Gerfaud-Valentin M, Hot A. et al. Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients. Rheumatology (Oxford) 2022; 61 (09) 3627-3639
• 49 Fanouriakis A, Kostopoulou M, Andersen J. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024; 83 (01) 15-29
• 50 Khellaf M, Chabrol A, Mahevas M. et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol 2014; 89 (02) 194-198
• 51 Roche O, Aladjidi N, Rakotonjanahary J. et al. Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP). Am J Hematol 2017; 92 (05) E79-E81
• 52 Serris A, Amoura Z, Canouï-Poitrine F. et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol 2018; 93 (03) 424-429
• 53 Sun F, Chen J, Wu W. et al. Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. Clin Rheumatol 2020; 39 (10) 3099-3104
• 54 Du H, Su W, Su J. et al. Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study. Rheumatology (Oxford) 2024; 63 (01) 79-84
• 55 Ulutaş F, Ök ZD, Uğur K, Çobankara V. Successful treatment of systemic lupus erythematosus-associated thrombocytopenia with eltrombopag: a report of two cases and literature review. Mediterr J Rheumatol 2022; 33 (04) 444-448
• 56 Garra W, Carmi O, Kivity S, Levy Y. Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review. Medicine (Baltimore) 2023; 102 (06) e32949
• 57 Van de Vondel S, Vandenbriele C, Gheysens G, Verhamme P, Janssens A. Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag. Res Pract Thromb Haemost 2023; 7 (03) 100125
• 58 Roeser A, Lazarus AH, Mahévas M. B cells and antibodies in refractory immune thrombocytopenia. Br J Haematol 2023; 203 (01) 43-53
• 59 Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119 (07) 1650-1657
• 60 Gathmann B, Mahlaoui N, Gérard L. et al; CEREDIH, Dutch WID, European Society for Immunodeficiencies Registry Working Party. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134 (01) 116-126
• 61 Wehr C, Kivioja T, Schmitt C. et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111 (01) 77-85
• 62 Sánchez-Ramón S, Radigan L, Yu JE, Bard S, Cunningham-Rundles C. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol 2008; 128 (03) 314-321
• 63 Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol 2007; 124 (02) 182-189
• 64 Roskin KM, Simchoni N, Liu Y. et al. IgH sequences in common variable immune deficiency reveal altered B cell development and selection. Sci Transl Med 2015; 7 (302) 302ra135
• 65 Bateman EAL, Ayers L, Sadler R. et al. T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections. Clin Exp Immunol 2012; 170 (02) 202-211
• 66 Berbers RM, van der Wal MM, van Montfrans JM. et al. Chronically activated T-cells retain their inflammatory properties in common variable immunodeficiency. J Clin Immunol 2021; 41 (07) 1621-1632
• 67 Abolhassani H, Hammarström L, Cunningham-Rundles C. Current genetic landscape in common variable immune deficiency. Blood 2020; 135 (09) 656-667
• 68 Rojas-Restrepo J, Caballero-Oteyza A, Huebscher K. et al. Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: experience from a monocentric study. Front Immunol 2021; 12: 786516
• 69 Cunningham-Rundles C, Casanova JL, Boisson B. Genetics and clinical phenotypes in common variable immunodeficiency. Front Genet 2024; 14: 1272912
• 70 Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25 (01) 57-62
• 71 Gobert D, Bussel JB, Cunningham-Rundles C. et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011; 155 (04) 498-508
• 72 Carrabba M, Barcellini W, Fabio G. Use of thrombopoietin-receptor agonist in CVID-associated immune thrombocytopenia. J Clin Immunol 2016; 36 (05) 434-436
• 73 Wong GK, Goldacker S, Winterhalter C. et al; Clinical Working Party of the European Society for Immunodeficiencies (ESID). Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. Clin Exp Immunol 2013; 172 (01) 63-72
• 74 Cohen JJ, Bansmer C. Chicken pox with simultaneous idiopathic thrombocytopenic purpura; report of a case. N Engl J Med 1947; 237 (07) 222-224
• 75 Bayer WL, Sherman FE, Michaels RH, Szeto ILF, Lewis JH. Purpura in congenital and acquired rubella. N Engl J Med 1965; 273 (25) 1362-1366
• 76 Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46 (1, Suppl 2): S2-S14
• 77 Gasbarrini A, Franceschi F, Tartaglione R. et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352 (9131) 878
• 78 Stasi R, Sarpatwari A, Segal JB. et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113 (06) 1231-1240
• 79 Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?. Blood 2004; 103 (03) 890-896
• 80 Losada PX, DeLaura I, Narváez CF. Dengue virus and platelets: from the biology to the clinic. Viral Immunol 2022; 35 (05) 349-358
• 81 Haward R, Konjeti S, Chacko J, Nadella JS, Roja SL, Rayapudi JJ. Papaya leaf extract elevates platelet levels in individuals with dengue fever. Cureus 2024; 16 (05) e61090
• 82 Morris L, Distenfeld A, Amorosi E, Karpatkin S. Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med 1982; 96 (6 Pt 1): 714-717
• 83 Kaslow RA, Phair JP, Friedman HB. et al. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 1987; 107 (04) 474-480
• 84 Sloand EM, Klein HG, Banks SM, Vareldzis B, Merritt S, Pierce P. Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol 1992; 48 (03) 168-172
• 85 Mientjes GH, van Ameijden EJ, Mulder JW, van den Hoek JA, Coutinho RA, von dem Borne AE. Prevalence of thrombocytopenia in HIV-infected and non-HIV infected drug users and homosexual men. Br J Haematol 1992; 82 (03) 615-619
• 86 Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 (04) 374-379
• 87 Quaranta JF, Delaney SR, Alleman S, Cassuto JP, Dellamonica P, Allain JP. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J Med Virol 1994; 42 (01) 29-32
• 88 Aboulafia DM, Bundow D, Waide S, Bennet C, Kerr D. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. Am J Med Sci 2000; 320 (02) 117-123
• 89 Servais J, Nkoghe D, Schmit JC. et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28 (03) 221-225
• 90 Rarick MU, Loureiro C, Groshen S. et al. Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia. J Acquir Immune Defic Syndr 1991; 4 (06) 593-597
• 91 Walsh C, Krigel R, Lennette E, Karpatkin S. Thrombocytopenia in homosexual patients. Prognosis, response to therapy, and prevalence of antibody to the retrovirus associated with the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103 (04) 542-545
• 92 Oksenhendler E, Bierling P, Chevret S. et al. Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia. Blood 1993; 82 (01) 29-32
• 93 Scaradavou A, Woo B, Woloski BMR. et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89 (08) 2689-2700
• 94 Ambler KLS, Vickars LM, Leger CS. et al. Clinical features, treatment, and outcome of HIV-associated immune thrombocytopenia in the HAART era. Adv Hematol 2012; 2012: 910954
• 95 Kowalczyk M, Rubinstein PG, Aboulafia DM. Initial experience with the use of thrombopoetin receptor agonists in patients with refractory HIV-associated immune thrombocytopenic purpura: a case series. J Int Assoc Provid AIDS Care 2015; 14 (03) 211-216
• 96 Marroni M, Gresele P, Landonio G. et al. Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial. Ann Intern Med 1994; 121 (06) 423-429
• 97 García-Suárez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant α2b-interferon therapy. Br J Haematol 2000; 110 (01) 98-103
• 98 Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 2001; 68 (03) 202-209
• 99 Zuckerman AJ. The elusive hepatitis C virus. BMJ 1989; 299 (6704): 871-873
• 100 Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144 (10) 705-714
• 101 Pyrsopoulos NT, Reddy KR. Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep 2001; 3 (01) 71-78
• 102 Cacoub P, Renou C, Rosenthal E. et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79 (01) 47-56
• 103 Songtanin B, Nugent K. Burden, outcome, and comorbidities of extrahepatic manifestations in hepatitis C virus infection. Biology (Basel) 2022; 12 (01) 23
• 104 Liebman HA. Viral-associated immune thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2008; x: 212-218
• 105 Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 2005; 129 (06) 818-824
• 106 Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S. Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia. Ther Clin Risk Manag 2019; 15: 269-274
• 107 Terrault N, Chen YC, Izumi N. et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology 2018; 155 (03) 705-718
• 108 Johira Y, Hatooka H, Mori N. et al. Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals. Hepatology 2020; 71 (01) 389-391
• 109 Satoh T, Uojima H, Wada N. et al. Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia. Platelets 2023; 34 (01) 2161498
• 110 Arena R, Cecinato P, Lisotti A. et al. Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: a case report and systematic review of literature. World J Hepatol 2015; 7 (12) 1718-1722
• 111 Oski FA, Naiman JL. Effect of live measles vaccine on the platelet count. N Engl J Med 1966; 275 (07) 352-356
• 112 Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993; 82 (03) 267-270
• 113 Stratton KR, Howe CJ, Johnston Jr RB. eds. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. National Academies Press; 1994
• 114 Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010; 156 (04) 623-628
• 115 Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16) 4190-4207
• 116 Mericliler M. Comparative analysis of de novo immune thrombocytopenia following mRNA COVID-19 vaccine versus non-mRNA vaccines and COVID-19: a global database analysis. Cureus 2023; 15 (07) e41460

Publikationsverlauf

Eingereicht: 07. November 2024

Angenommen: 18. Dezember 2024

Accepted Manuscript online:
24. Dezember 2024

Artikel online veröffentlicht:
20. Januar 2025